Patent intelligence · US
US 10441590
Methods for treating pulmonary hypertension
Methods for treating pulmonary hypertension
Patent details — US 10441590
- Jurisdiction
- US
- Status
- granted
- Grant date
- Oct 15, 2019
- Expiration
- Oct 10, 2039
- Applicant
- REVIVA PHARMACEUTICALS, INC.
- Claims
- 10
- CPC classes
- A61K, A61K31/538, A61P, A61P25/22
Quick answer
US 10441590 (Methods for treating pulmonary hypertension) is held by REVIVA PHARMACEUTICALS, INC.. Status: granted. Granted Oct 15, 2019. Expires Oct 10, 2039 (13 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- REVIVA PHARMACEUTICALS, INC.
- Grant date
- Expiration
- Claims
- 10
- CPC classes
- A61K, A61K31/538, A61P, A61P25/22, A61P25/24, A61P9/12
More from REVIVA PHARMACEUTICALS, INC.
Related pharmaceutical patents in our USPTO index.
-
US 12053477
Methods for treating pulmonary fibrosis
granted -
US 10035761
Compositions, synthesis, and methods of using phenylcycloalkylmethylamine derivatives
granted -
US 9975862
Arylpiperazine derivatives and methods of utilizing same
granted -
US 9907803
Methods for treating attention deficit hyperactivity disorder
granted -
US 9695116
Compositions, synthesis, and methods of using phenylcycloalkylmethylamine derivatives
granted -
US 9604944
Arylpiperazine derivatives and methods of utilizing same
granted -
US 9302981
Synthesis, methods of using, and compositions of cycloalkylmethylamines
granted
Frequently asked questions
What is US patent 10441590?
US 10441590 (Methods for treating pulmonary hypertension) is held by REVIVA PHARMACEUTICALS, INC.. Status: granted. Granted Oct 15, 2019. Expires Oct 10, 2039 (13 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 10441590?
REVIVA PHARMACEUTICALS, INC. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 28 pharmaceutical patents for this assignee.
When does US 10441590 expire?
Our index shows an expiration date of Oct 10, 2039 (13 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.